Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Low Grade Endometrioid AdenocarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Low Grade Endometrioid AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma
Interventions
DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Electrocardiography

Undergo ECG

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Tuvusertib

Given PO

PROCEDURE

X-Ray Imaging

Undergo x-ray

Trial Locations (14)

19103

RECRUITING

NRG Oncology, Philadelphia

19104

SUSPENDED

University of Pennsylvania/Abramson Cancer Center, Philadelphia

19107

RECRUITING

Thomas Jefferson University Hospital, Philadelphia

30912

SUSPENDED

Augusta University Medical Center, Augusta

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

44106

ACTIVE_NOT_RECRUITING

Case Western Reserve University, Cleveland

44195

RECRUITING

Cleveland Clinic Foundation, Cleveland

48201

RECRUITING

Wayne State University/Karmanos Cancer Institute, Detroit

52242

RECRUITING

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

87106

RECRUITING

University of New Mexico Cancer Center, Albuquerque

02905

RECRUITING

Women and Infants Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH